References
- 1. Varma, R., R. Garrick, J. McClung, and W. H. Frishman. 2005. Chronic renal dysfunction as an independent risk factor for the development of cardiovascular disease. Cardiology in review 13: 98-107.10.1097/01.crd.0000132600.45876.d0
- 2. Chow, K. M., C. C. Szeto, C. B. Leung, B. C. Kwan, M. C. Law, and P. K. Li. 2005. A risk analysis of continuous ambulatory peritoneal dialysis-related peritonitis. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 25: 374-379.
- 3. Stewart, C. L., S. N. Acker, L. L. Pyle, A. Kulungowski, M. Cadnapaphornchai, J. L. Bruny, and F. Karrer. 2016. Factors associated with peritoneal dialysis catheter complications in children. Journal of pediatric surgery 51: 159-162.
- 4. Ratajczak, A., M. Lange-Ratajczak, A. Bobkiewicz, and A. Studniarek. 2017. Surgical Management of Complications with Perito-neal Dialysis. Seminars in Dialysis 30: 63-68.
- 5. Wang, L.-J., and C.-K. Che. 2012. The Psychological Impact of Hemodialysis on Patients with Chronic Renal Failure.
- 6. Depner, T. A., and L. D. Cowgill. 2014. Can oral therapy reduce uremic toxins? Clin J Am Soc Nephrol 9: 1513-1515.2514715610.2215/CJN.07330714
- 7. Jain, P., S. Shah, R. Coussa, and S. Prakash. 2009. Potentials and limitations of microorganisms as renal failure biotherapeutics. Biologics 3: 233-243.19707412
- 8. Vaziri, N. D., J. Yuan, M. Khazaeli, Y. Masuda, H. Ichii, and S. Liu. 2013. Oral Activated Charcoal Adsorbent (AST-120) Ameliorates Chronic Kidney Disease-Induced Intestinal Epithelial Barrier Disruption. American Journal of Nephrology 37: 518-525.
- 9. Dhondt, A., R. Vanholder, W. Van Biesen, and N. Lameire. 2000. The removal of uremic toxins. Kidney International 58: S47-S59.10.1046/j.1523-1755.2000.07606.x
- 10. Clark, J. E., J. Y. Templeton, 3rd, and C. D. Mc. 1962. Perfusion of isolated intestinal loops in the management of chronic renal failure. Transactions - American Society for Artificial Internal Organs 8: 246-251.
- 11. Parisi, R. 1969. Management of chronic renal failure by isolated jejunal loop perfusion. British journal of urology 41: 603-604.
- 12. Goto, S., K. Yoshiya, T. Kita, H. Fujii, and M. Fukagawa. 2011. Uremic toxins and oral adsorbents. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 15: 132-134.10.1111/j.1744-9987.2010.00891.x
- 13. Sato, E., D. Saigusa, E. Mishima, T. Uchida, D. Miura, T. Morikawa-Ichinose, K. Kisu, A. Sekimoto, R. Saito, Y. Oe, Y. Matsumoto, Y. Tomioka, T. Mori, N. Takahashi, H. Sato, T. Abe, T. Niwa, and S. Ito. 2017. Impact of the Oral Adsorbent AST-120 on Organ-Specific Accumulation of Uremic Toxins: LC-MS/MS and MS Imaging Techniques. Toxins (Basel) 10: 19.
- 14. Abidin, M. N. Z., P. S. Goh, A. F. Ismail, N. Said, M. H. D. Othman, H. Hasbullah, M. S. Abdullah, B. C. Ng, S. H. S. A. Kadir, and F. Kamal. 2018. Highly adsorptive oxidized starch nanoparticles for efficient urea removal. Carbohydrate Polymers 201: 257-263.
- 15. Chandy, T., and C. P. Sharma. 1998. Activated charcoal microcapsules and their applications. Journal of biomaterials applications 13: 128-157.
- 16. Sparks, R. E., N. S. Mason, P. M. Meier, M. H. Litt, and O. Lindan. 1971. Removal of uremic waste metabolites from the intestinal tract by encapsulated carbon and oxidized starch. Transactions-American Society for Artificial Internal Organs 17: 229-238.
- 17. Prakash, S., and T. M. S. Chang. 1996. Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nature Medicine 2: 883-887.10.1038/nm0896-883
- 18. Bhatia, A., P. Rana, A. Sharma, R. Singla, and M. K. Randhawa. 2012. Preparation, characterization and hypocholesterolemic effect of sodium alginate encapsulated lab isolate. Journal of Microbiology and Biotechnology Research 2: 741-746.
- 19. Solga, S. F. 2003. Probiotics can treat hepatic encephalopathy. Medical Hypotheses 61: 307-313.10.1016/S0306-9877(03)00192-0
- 20. Iqbal, U. H., S. Westfall, and S. Prakash. 2018. Novel microencapsulated probiotic blend for use in metabolic syndrome: design and in-vivo analysis. Artificial cells, nanomedicine, and biotechnology 46: S116-s124.
- 21. Westfall, S., N. Lomis, and S. Prakash. 2019. A novel synbiotic delays Alzheimer’s disease onset via combinatorial gut-brain-axis signaling in Drosophila melanogaster. PLOS ONE 14: e0214985.
- 22. Prakash, S., and T. M. Chang. 1995. Preparation and in vitro analysis of microencapsulated genetically engineered E. coli DH5 cells for urea and ammonia removal. Biotechnology and bioengineering 46: 621-626.10.1002/bit.260460615
- 23. Dehghani, H., F. Heidari, H. Mozaffari-Khosravi, N. Nouri-Majelan, and A. Dehghani. 2016. Synbiotic Supplementations for Azotemia in Patients With Chronic Kidney Disease: a Randomized Controlled Trial. Iranian journal of kidney diseases 10: 351-357.
- 24. Firouzi, S., B.-N. Mohd-Yusof, H.-A. Majid, A. Ismail, and N.-A. Kamaruddin. 2015. Effect of microbial cell preparation on renal profile and liver function among type 2 diabetics: a randomized controlled trial. BMC Complement Altern Med 15: 433-433.
- 25. Natarajan, R., B. Pechenyak, U. Vyas, P. Ranganathan, A. Weinberg, P. Liang, M. C. Mallappallil, A. J. Norin, E. A. Friedman, and S. J. Saggi. 2014. Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. Biomed Res Int 2014: 568571-568571.